

THE AM LAW LITIGATION DAILY

Litigator of the Week Runners-Up and Shout-Outs

By Ross Todd

August 22, 2025

► Last year, after a federal judge in Las Vegas dismissed antitrust litigation targeting the use of algorithmic pricing tools by hotels on the Vegas Strip, we tapped Boris Bershteyn of Skadden, Arps, Slate, Meagher & Flom, who represents Caesars Entertainment, and **Brendan McShane** of **Latham & Watkins**, who represents hospitality technology company Cendyn Group, as [Litigators of the Week](#). Last week, the Ninth Circuit, in [a published opinion, affirmed the dismissal](#). “Neither the terms nor the operation of the licensing agreements are alleged to have harmed competition by affecting the competitive incentives,” wrote Ninth Circuit Senior Judge Carlos Bea of the hotels’ separate agreements to license Cendyn’s price-recommendation software. The **Latham** team representing Cendyn included McShane, **Melissa Arbus Sherry**, who argued the appeal on behalf of all defendants, partners **Sadik Huseny** and **Anna Rathbun** and associates **Christopher Brown** and **Graham Haviland**. The team at Skadden representing Caesars Entertainment included Bershteyn, Ken Schwartz, Michael Menitove and Sam Auld. The team representing Wynn Resorts Holdings at Kirkland & Ellis includes Mark Holscher and Tammy Tsoumas. The team representing Treasure Island includes Patrick Reilly, Arthur Zorio, Emily Garnett and Eric Walther of Brownstein Hyatt Farber Schreck. The team representing Blackstone Inc. and Blackstone Real Estate Partners VII includes Matthew McGinnis of Ropes & Gray. The team representing The Rainmaker Group Unlimited includes Arman Oruc and Alicia Rubio-Spring of Goodwin Procter and Nicholas Santoro of Spencer Fane. The team representing JC Hospitality includes Kasey Curtis and Charles Hyun of Reed Smith.

► Shout-out to a team at **Latham & Watkins** that secured [a summary judgment defense win](#) in securities litigation for pharmaceutical client ChemoCentryx, which had been accused of overstating the safety and effectiveness of its treatment for the rare autoimmune disease ANCA vasculitis. U.S. District Judge Jon Tigar in San Francisco last week found that the 100-plus statements challenged by the plaintiffs were opinions interpreting clinical trial data. Tigar further found that allegations that the FDA privately flagged issues during the regulatory process didn’t render the company’s expressions of optimism false. The **Latham** team was led by partners **Michele Johnson**, **Andrew Clubok**, **Colleen Smith** and **Susan Engel**.